Morgan Stanley analyst Tejas Savant maintained a Buy rating on 10x Genomics (TXG – Research Report) today and set a price target of $26.00. The company’s shares closed yesterday at $11.94.

Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 8.5% in the pre-market session after the company reported disappointing fourth-quarter results: its EPS missed significantly, and its full ...

Biotech company 10x Genomics (NASDAQ:TXG) will be reporting earnings tomorrow after market hours. Here’s what to look for. 10x Genomics missed analysts’ revenue expectations by 5% last quarter ...

TXG opened at $12.31 on Thursday. The stock has a market cap of $1.49 billion, a price-to-earnings ratio of -8.05 and a beta of 1.85. 10x Genomics has a 1 year low of $10.80 and a 1 year high of ...

10x Genomics (NASDAQ:TXG – Get Free Report) had its price objective reduced by Morgan Stanley from $28.00 to $26.00 in a research report issued to clients and investors on Friday,Benzinga reports.

In trading on Monday, shares of 10x Genomics Inc (Symbol: TXG) entered into oversold territory, hitting an RSI reading of 27.9, after changing hands as low as $11.8955 per share. By comparison ...

And no one really knows with certainty what the final outcome of those various announced changes will be. And so as such, we have not incorporated these more recent events the indirect ...

In a report released today, Michael Ryskin from Bank of America Securities maintained a Hold rating on 10x Genomics (TXG – Research Report). The company’s shares opened today at $14.74.